US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Cartesian Therapeutics

11.83

-0.2200-1.83%

Post-market: 11.830.00000.00%16:05 EDT

Volume:45.58K

Turnover:537.96K

Market Cap:306.48M

PE:-2.64

High:12.05

Open:11.87

Low:11.51

Close:12.05

Loading ...

Overview Company News Filings

Cartesian Therapeutics: Phase 3 Aurora Trial of Descartes-08 in Myasthenia Gravis on Track to Commence in 1H25

THOMSON REUTERS

Cartesian Therapeutics : Phase 2 Trial of Descartes-08 in Systemic Lupus Erythematosus Ongoing With Expected Data Readout in 2H25

THOMSON REUTERS

Cartesian Therapeutics : Expects to Initiate Phase 2 Pediatric Basket Trial of Decartes-08 in Select Autoimmune Indications in 2H25

THOMSON REUTERS

Cartesian Therapeutics announces employment inducement grant

Cartesian Therapeutics Announces New Employment Inducement Grant

Cartesian Therapeutics Inc expected to post a loss of 80 cents a share - Earnings Preview

Innovative mRNA-Based CAR-T Therapy Positions Cartesian Therapeutics for Market Leadership

Yale University Exits Cartesian Therapeutics Inc, Impacting Portfolio by -66.5%

Promising Developments and Strategic Expansion Bolster Buy Rating for Cartesian Therapeutics

Cartesian Therapeutics Says US FDA Agrees to Phase 3 Myasthenia Gravis Trial Design

MT Newswires Live

Cartesian Therapeutics Price Target Maintained With a $41.00/Share by Needham

Positive Buy Rating for Cartesian Therapeutics Amid Encouraging Developments in Descartes-08 Trials

Cartesian Therapeutics Announces FDA Special Protocol Assessment Agreement for Phase 3 Aurora Trial of Descartes-08 in Myasthenia Gravis

THOMSON REUTERS

Promising Developments and Strategic Milestones Drive Buy Rating for Cartesian Therapeutics

Cartesian Therapeutics Price Target Maintained With a $41.00/Share by Needham

Buy Rating for Cartesian Therapeutics Driven by Promising Clinical Pipeline and Financial Stability

BRIEF-Cartesian Therapeutics Highlights Progress And 2025 Strategic Priorities

Cartesian Therapeutics Highlights Progress and 2025 Strategic Priorities Across Pipeline of Mrna Cell Therapies for Autoimmune Diseases

THOMSON REUTERS

Cartesian Therapeutics Inc - Phase 3 Aurora Trial of Descartes-08 to Commence in 1H25

THOMSON REUTERS

Cartesian Therapeutics Inc - Cash Resources Expected to Support Operations Into Mid-2027

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/RNAC/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"RNAC","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RNAC\",,,,,undefined,":{"symbol":"RNAC","market":"US","secType":"STK","nameCN":"Cartesian Therapeutics","latestPrice":11.83,"timestamp":1745611200000,"preClose":12.05,"halted":0,"volume":45578,"hourTrading":{"tag":"盘后","latestPrice":11.83,"preClose":11.83,"latestTime":"16:05 EDT","volume":578,"amount":6837.74,"timestamp":1745611508483},"delay":0,"floatShares":9302905,"shares":25907101,"eps":-4.48613,"marketStatus":"Market Closed","change":-0.22,"latestTime":"04-25 16:00:00 EDT","open":11.87,"high":12.05,"low":11.5074,"amount":537961.4995,"amplitude":0.045029,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-4.48613,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1745827200000},"marketStatusCode":7,"adr":0,"listingDate":1466568000000,"exchange":"NASDAQ","adjPreClose":12.05,"preHourTrading":{"tag":"盘前","latestPrice":11.92,"preClose":12.05,"latestTime":"04:48 EDT","volume":3,"amount":35.440000500000004,"timestamp":1745570908669},"postHourTrading":{"tag":"盘后","latestPrice":11.83,"preClose":11.83,"latestTime":"16:05 EDT","volume":578,"amount":6837.74,"timestamp":1745611508483},"volumeRatio":0.5714737090496524,"impliedVol":1.1151,"impliedVolPercentile":0.4286},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RNAC\",,,,,undefined,":{"symbol":"RNAC","floatShares":9302905,"roa":"-6.00%","roe":"-7029.26%","lyrEps":-4.481379,"volumeRatio":0.5714737090496524,"shares":25907101,"dividePrice":0,"high":12.05,"amplitude":0.045029,"preClose":12.05,"low":11.5074,"week52Low":8.85,"pbRate":"-45.06","psRate":"7.88","week52High":41.87,"institutionHeld":0,"latestPrice":11.83,"eps":-4.48613,"divideRate":0,"volume":45578,"delay":0,"ttmEps":-4.48613,"open":11.87,"prevYearClose":17.91,"prevWeekClose":10.5,"prevMonthClose":13.18,"prevQuarterClose":13.18,"fiveDayClose":10.5,"twentyDayClose":14.36,"sixtyDayClose":19.23},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"RNAC\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2519887770","title":"Cartesian Therapeutics: Phase 3 Aurora Trial of Descartes-08 in Myasthenia Gravis on Track to Commence in 1H25","url":"https://stock-news.laohu8.com/highlight/detail?id=2519887770","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519887770?lang=en_us&edition=fundamental","pubTime":"2025-03-13 19:07","pubTimestamp":1741864070,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250313:nFWN3PW0S9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RNAC","BK4139"],"gpt_icon":0},{"id":"2519887705","title":"Cartesian Therapeutics : Phase 2 Trial of Descartes-08 in Systemic Lupus Erythematosus Ongoing With Expected Data Readout in 2H25","url":"https://stock-news.laohu8.com/highlight/detail?id=2519887705","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519887705?lang=en_us&edition=fundamental","pubTime":"2025-03-13 19:07","pubTimestamp":1741864070,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250313:nFWN3PW0S9:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","RNAC"],"gpt_icon":0},{"id":"2519788777","title":"Cartesian Therapeutics :  Expects to Initiate Phase 2 Pediatric Basket Trial of Decartes-08 in Select Autoimmune Indications in 2H25","url":"https://stock-news.laohu8.com/highlight/detail?id=2519788777","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519788777?lang=en_us&edition=fundamental","pubTime":"2025-03-13 19:07","pubTimestamp":1741864070,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250313:nFWN3PW0S9:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RNAC","BK4139"],"gpt_icon":0},{"id":"2517615995","title":"Cartesian Therapeutics announces employment inducement grant","url":"https://stock-news.laohu8.com/highlight/detail?id=2517615995","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517615995?lang=en_us&edition=fundamental","pubTime":"2025-03-06 20:12","pubTimestamp":1741263154,"startTime":"0","endTime":"0","summary":"Cartesian Therapeutics (RNAC) announced the granting of an inducement award to one new employee. On March 3, 2025, the Company issued to this emplo...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cartesian-therapeutics-announces-employment-inducement-grant-4?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cartesian-therapeutics-announces-employment-inducement-grant-4?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","RNAC"],"gpt_icon":0},{"id":"2517156019","title":"Cartesian Therapeutics Announces New Employment Inducement Grant","url":"https://stock-news.laohu8.com/highlight/detail?id=2517156019","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517156019?lang=en_us&edition=fundamental","pubTime":"2025-03-06 20:05","pubTimestamp":1741262700,"startTime":"0","endTime":"0","summary":"FREDERICK, Md., March  06, 2025  (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapies for the treatmen","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/06/3038073/0/en/Cartesian-Therapeutics-Announces-New-Employment-Inducement-Grant.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RNAC","BK4139"],"gpt_icon":0},{"id":"2516866636","title":"Cartesian Therapeutics Inc  expected to post a loss of 80 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2516866636","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516866636?lang=en_us&edition=fundamental","pubTime":"2025-03-03 21:32","pubTimestamp":1741008764,"startTime":"0","endTime":"0","summary":"Cartesian Therapeutics Inc  expected to post a loss of80cents a share - Earnings Preview Cartesian Therapeutics Inc RNAC.OQ RNAC.O is expected to show a fall in quarterly revenue when it reports  resu","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250303:nL5N3PM11T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RNAC"],"gpt_icon":0},{"id":"2514876826","title":"Innovative mRNA-Based CAR-T Therapy Positions Cartesian Therapeutics for Market Leadership","url":"https://stock-news.laohu8.com/highlight/detail?id=2514876826","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514876826?lang=en_us&edition=fundamental","pubTime":"2025-02-27 17:35","pubTimestamp":1740648959,"startTime":"0","endTime":"0","summary":"Thomas Smith, an analyst from Leerink Partners, maintained the Buy rating on Cartesian Therapeutics (RNAC – Research Report). The associated price ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/innovative-mrna-based-car-t-therapy-positions-cartesian-therapeutics-for-market-leadership?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/innovative-mrna-based-car-t-therapy-positions-cartesian-therapeutics-for-market-leadership?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CAR","BK4139","RNAC","BK4022","BK4230"],"gpt_icon":0},{"id":"2511869750","title":"Yale University Exits Cartesian Therapeutics Inc, Impacting Portfolio by -66.5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2511869750","media":"GuruFocus","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511869750?lang=en_us&edition=fundamental","pubTime":"2025-02-15 00:03","pubTimestamp":1739549003,"startTime":"0","endTime":"0","summary":"Insight into Yale University (Trades, Portfolio)'s Strategic Investment Moves Yale University (Trades, Portfolio) recently submitted its 13F filing for the fourth quarter of 2024, offering a glimpse i","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gurufocus.com/news/2698916/yale-university-exits-cartesian-therapeutics-inc-impacting-portfolio-by-665","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"gurufocus_highlight","symbols":["BK4585","BK4588","BK4550","BK4139","ITOT","RNAC"],"gpt_icon":0},{"id":"2507150995","title":"Promising Developments and Strategic Expansion Bolster Buy Rating for Cartesian Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2507150995","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507150995?lang=en_us&edition=fundamental","pubTime":"2025-01-29 14:16","pubTimestamp":1738131363,"startTime":"0","endTime":"0","summary":"Leerink Partners analyst Thomas Smith has reiterated their bullish stance on RNAC stock, giving a Buy rating yesterday. Thomas Smith’s rating is ba...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/promising-developments-and-strategic-expansion-bolster-buy-rating-for-cartesian-therapeutics?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/promising-developments-and-strategic-expansion-bolster-buy-rating-for-cartesian-therapeutics?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RNAC"],"gpt_icon":0},{"id":"2506305691","title":"Cartesian Therapeutics Says US FDA Agrees to Phase 3 Myasthenia Gravis Trial Design","url":"https://stock-news.laohu8.com/highlight/detail?id=2506305691","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506305691?lang=en_us&edition=fundamental","pubTime":"2025-01-27 23:01","pubTimestamp":1737990086,"startTime":"0","endTime":"0","summary":"Cartesian Therapeutics  said Monday the US Food and Drug Administration has agreed to the design of its phase 3 AURORA trial for Descartes-08, its mRNA cell therapy for myasthenia gravis, a chronic autoimmune disorder that causes muscle weakness.The company said the randomized trial, expected to begin in H1, will compare Descartes-08 to a placebo in about 100 participants with acetylcholine receptor autoantibody-positive myasthenia gravis.The primary endpoint will measure the percentage of patients with a three-point or greater improvement in myasthenia gravis activities of daily living scores after four months, Cartesian added.Shares of the company were up 2.9% in recent Monday trading.Price: 19.76, Change: +0.56, Percent Change: +2.89","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["RNAC","BK4139"],"gpt_icon":0},{"id":"2506370866","title":"Cartesian Therapeutics Price Target Maintained With a $41.00/Share by Needham","url":"https://stock-news.laohu8.com/highlight/detail?id=2506370866","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506370866?lang=en_us&edition=fundamental","pubTime":"2025-01-27 21:31","pubTimestamp":1737984660,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/RNAC/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 27, 2025 08:31 ET (13:31 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RNAC"],"gpt_icon":0},{"id":"2506747953","title":"Positive Buy Rating for Cartesian Therapeutics Amid Encouraging Developments in Descartes-08 Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2506747953","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506747953?lang=en_us&edition=fundamental","pubTime":"2025-01-27 21:15","pubTimestamp":1737983715,"startTime":"0","endTime":"0","summary":"In a report released today, Gil Blum from Needham maintained a Buy rating on Cartesian Therapeutics (RNAC – Research Report), with a price target o...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/positive-buy-rating-for-cartesian-therapeutics-amid-encouraging-developments-in-descartes-08-trials?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/positive-buy-rating-for-cartesian-therapeutics-amid-encouraging-developments-in-descartes-08-trials?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RNAC","DSGX"],"gpt_icon":0},{"id":"2506751713","title":"Cartesian Therapeutics Announces FDA Special Protocol Assessment Agreement for Phase 3 Aurora Trial of Descartes-08 in Myasthenia Gravis","url":"https://stock-news.laohu8.com/highlight/detail?id=2506751713","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506751713?lang=en_us&edition=fundamental","pubTime":"2025-01-27 20:00","pubTimestamp":1737979202,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250127:nTUA8DYN4M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","RNAC"],"gpt_icon":0},{"id":"2503667312","title":"Promising Developments and Strategic Milestones Drive Buy Rating for Cartesian Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2503667312","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503667312?lang=en_us&edition=fundamental","pubTime":"2025-01-15 15:13","pubTimestamp":1736925228,"startTime":"0","endTime":"0","summary":"Leerink Partners analyst Thomas Smith has reiterated their bullish stance on RNAC stock, giving a Buy rating on January 13. Thomas Smith has given ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/promising-developments-and-strategic-milestones-drive-buy-rating-for-cartesian-therapeutics?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/promising-developments-and-strategic-milestones-drive-buy-rating-for-cartesian-therapeutics?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RNAC"],"gpt_icon":0},{"id":"2503876205","title":"Cartesian Therapeutics Price Target Maintained With a $41.00/Share by Needham","url":"https://stock-news.laohu8.com/highlight/detail?id=2503876205","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503876205?lang=en_us&edition=fundamental","pubTime":"2025-01-14 00:29","pubTimestamp":1736785740,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/RNAC/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 13, 2025 11:29 ET (16:29 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RNAC"],"gpt_icon":0},{"id":"2503582663","title":"Buy Rating for Cartesian Therapeutics Driven by Promising Clinical Pipeline and Financial Stability","url":"https://stock-news.laohu8.com/highlight/detail?id=2503582663","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503582663?lang=en_us&edition=fundamental","pubTime":"2025-01-14 00:15","pubTimestamp":1736784939,"startTime":"0","endTime":"0","summary":"Needham analyst Gil Blum maintained a Buy rating on Cartesian Therapeutics (RNAC – Research Report) today and set a price target of $41.00. Gil Blu...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/buy-rating-for-cartesian-therapeutics-driven-by-promising-clinical-pipeline-and-financial-stability?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/buy-rating-for-cartesian-therapeutics-driven-by-promising-clinical-pipeline-and-financial-stability?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RNAC"],"gpt_icon":0},{"id":"2503630424","title":"BRIEF-Cartesian Therapeutics Highlights Progress And 2025 Strategic Priorities","url":"https://stock-news.laohu8.com/highlight/detail?id=2503630424","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503630424?lang=en_us&edition=fundamental","pubTime":"2025-01-13 21:39","pubTimestamp":1736775550,"startTime":"0","endTime":"0","summary":"Jan 13  - Cartesian Therapeutics Inc   :   * CARTESIAN THERAPEUTICS HIGHLIGHTS PROGRESS AND 2025 STRATEGIC PRIORITIES ACROSS PIPELINE OF MRNA CELL THERAPIES FOR AUTOIMMUNE DISEASES   * CASH RESOURCES EXPECTED TO SUPPORT OPERATIONS INTO MID-2027   * PHASE 3 AURORA TRIAL OF DESCARTES-08 TO COMMENCE IN 1H25   * PHASE 2 SLE TRIAL OF DESCARTES-08 ONGOING, DATA READOUT EXPECTED 2H25Source text:    Further company coverage:    ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU2065732104.USD","RNAC","BK4097","PRGS"],"gpt_icon":0},{"id":"2503970308","title":"Cartesian Therapeutics Highlights Progress and 2025 Strategic Priorities Across Pipeline of Mrna Cell Therapies for Autoimmune Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2503970308","media":"THOMSON REUTERS","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503970308?lang=en_us&edition=fundamental","pubTime":"2025-01-13 20:00","pubTimestamp":1736769601,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250113:nTUANDMGZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","RNAC"],"gpt_icon":0},{"id":"2503308458","title":"Cartesian Therapeutics Inc - Phase 3 Aurora Trial of Descartes-08 to Commence in 1H25","url":"https://stock-news.laohu8.com/highlight/detail?id=2503308458","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503308458?lang=en_us&edition=fundamental","pubTime":"2025-01-13 20:00","pubTimestamp":1736769601,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250113:nTUANDMGZ:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","RNAC"],"gpt_icon":0},{"id":"2503120308","title":"Cartesian Therapeutics Inc - Cash Resources Expected to Support Operations Into Mid-2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2503120308","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503120308?lang=en_us&edition=fundamental","pubTime":"2025-01-13 20:00","pubTimestamp":1736769601,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250113:nTUANDMGZ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","RNAC"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":2,"totalSize":72,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/RNAC\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-03-13","symbol":"RNAC","fiscalQuarterEnding":"2024/12","expectedEps":-0.78,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1741838400000,"reportTimeType":"pre","actualEps":-2.4},{"market":"US","date":"2024-11-07","symbol":"RNAC","fiscalQuarterEnding":"2024/09","expectedEps":-0.78,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1730955600000,"reportTimeType":"pre","actualEps":-0.69},{"market":"US","date":"2024-08-08","symbol":"RNAC","fiscalQuarterEnding":"2024/06","expectedEps":-0.81,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1723089600000,"reportTimeType":"pre","actualEps":0.54},{"market":"US","date":"2024-05-08","symbol":"RNAC","fiscalQuarterEnding":"2024/03","expectedEps":-0.81,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1715140800000,"reportTimeType":"pre","actualEps":-1.97},{"market":"US","date":"2024-04-05","symbol":"RNAC","defaultRemindTime":1712323800000,"type":"split","dateTimestamp":1712289600000,"forFactor":30,"toFactor":1,"ratio":30}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"RNAC\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"RNAC\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.25,"buy":0.5,"hold":0.25,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5,"analysts":8,"updateTime":1734667200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/RNAC\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"RNAC","date":"2025-04-25","current":-4.03209,"percent":0.135417,"low":-14.109752,"twenty":-2.511189,"median":-1.940728,"eighty":-1.376163,"high":-0.322359,"avg":-2.801743,"sd":3.010294,"marketCap":312180567},"quantilePoints":[{"date":"2024-02-09","current":-12.195228,"twenty":-12.293822,"median":-12.139657,"eighty":-11.530164,"marketCap":110159496},{"date":"2024-02-16","current":-13.543282,"twenty":-12.82193,"median":-12.371802,"eighty":-12.018117,"marketCap":122336468},{"date":"2024-02-23","current":-12.9069,"twenty":-13.170416,"median":-12.72226,"eighty":-12.169773,"marketCap":116588031},{"date":"2024-03-01","current":-13.113052,"twenty":-13.187625,"median":-12.9069,"eighty":-12.193077,"marketCap":118450201},{"date":"2024-03-08","current":-0.474472,"twenty":-13.096919,"median":-12.72226,"eighty":-12.104521,"marketCap":104246325},{"date":"2024-03-15","current":-0.394571,"twenty":-13.085087,"median":-12.369113,"eighty":-0.499332,"marketCap":86691095},{"date":"2024-03-22","current":-0.518772,"twenty":-13.077916,"median":-12.18985,"eighty":-0.473381,"marketCap":113979437},{"date":"2024-03-28","current":-0.486782,"twenty":-13.018401,"median":-12.095738,"eighty":-0.472836,"marketCap":106950867},{"date":"2024-04-05","current":-0.371573,"twenty":-12.924109,"median":-11.522994,"eighty":-0.462369,"marketCap":81638284},{"date":"2024-04-12","current":-1.459867,"twenty":-12.9069,"median":-1.226402,"eighty":-0.444134,"marketCap":320747357},{"date":"2024-04-19","current":-1.398365,"twenty":-12.846668,"median":-1.459867,"eighty":-0.462369,"marketCap":307234719},{"date":"2024-04-26","current":-1.691309,"twenty":-12.729072,"median":-1.487381,"eighty":-0.467868,"marketCap":371597548},{"date":"2024-05-03","current":-1.978779,"twenty":-12.63227,"median":-1.536745,"eighty":-0.471303,"marketCap":434757574},{"date":"2024-05-10","current":-1.526348,"twenty":-12.47667,"median":-1.594687,"eighty":-0.472836,"marketCap":389021718},{"date":"2024-05-17","current":-1.839158,"twenty":-12.299559,"median":-1.62026,"eighty":-0.47633,"marketCap":468748036},{"date":"2024-05-24","current":-1.777713,"twenty":-12.193077,"median":-1.671483,"eighty":-0.482182,"marketCap":453087509},{"date":"2024-05-31","current":-2.195259,"twenty":-12.18985,"median":-1.697348,"eighty":-0.489671,"marketCap":559507906},{"date":"2024-06-07","current":-2.422885,"twenty":-12.179811,"median":-1.717665,"eighty":-0.504164,"marketCap":617523039},{"date":"2024-06-14","current":-2.045138,"twenty":-12.139657,"median":-1.777713,"eighty":-0.515905,"marketCap":521246392},{"date":"2024-06-21","current":-1.598266,"twenty":-12.069386,"median":-1.728138,"eighty":-0.518199,"marketCap":407351653},{"date":"2024-06-28","current":-1.991374,"twenty":-11.947846,"median":-1.777713,"eighty":-0.520305,"marketCap":507543431},{"date":"2024-07-05","current":-1.23169,"twenty":-11.531957,"median":-1.728138,"eighty":-0.526438,"marketCap":313922113},{"date":"2024-07-12","current":-1.241477,"twenty":-11.522994,"median":-1.709478,"eighty":-0.530124,"marketCap":316416386},{"date":"2024-07-15","current":-1.240079,"twenty":-9.729226,"median":-1.703386,"eighty":-0.53751,"marketCap":316060062},{"date":"2024-08-02","current":-1.081399,"twenty":-7.935458,"median":-1.699966,"eighty":-0.544895,"marketCap":275617201},{"date":"2024-08-09","current":-1.198323,"twenty":-2.548847,"median":-1.676743,"eighty":-0.772791,"marketCap":275192581},{"date":"2024-08-16","current":-1.345437,"twenty":-2.529995,"median":-1.625846,"eighty":-1.101689,"marketCap":308976908},{"date":"2024-08-23","current":-1.244878,"twenty":-2.507232,"median":-1.598266,"eighty":-1.148418,"marketCap":285883824},{"date":"2024-08-30","current":-1.388267,"twenty":-2.46827,"median":-1.531547,"eighty":-1.172903,"marketCap":318812851},{"date":"2024-09-06","current":-1.307262,"twenty":-2.424002,"median":-1.519153,"eighty":-1.173531,"marketCap":300210089},{"date":"2024-09-13","current":-1.496275,"twenty":-2.390626,"median":-1.497092,"eighty":-1.177113,"marketCap":343616533},{"date":"2024-09-20","current":-1.540036,"twenty":-2.248325,"median":-1.497406,"eighty":-1.182548,"marketCap":353666301},{"date":"2024-09-27","current":-1.616387,"twenty":-2.173184,"median":-1.49772,"eighty":-1.183457,"marketCap":371199939},{"date":"2024-10-04","current":-2.374287,"twenty":-2.173184,"median":-1.519153,"eighty":-1.187433,"marketCap":545250240},{"date":"2024-10-11","current":-2.176603,"twenty":-2.352646,"median":-1.530726,"eighty":-1.193387,"marketCap":499852543},{"date":"2024-10-18","current":-2.257757,"twenty":-2.310612,"median":-1.544226,"eighty":-1.200277,"marketCap":518489492},{"date":"2024-10-25","current":-2.299664,"twenty":-2.339564,"median":-1.569114,"eighty":-1.208188,"marketCap":528113202},{"date":"2024-10-31","current":-2.199769,"twenty":-2.325678,"median":-1.616387,"eighty":-1.208566,"marketCap":505172538},{"date":"2024-11-08","current":-2.028231,"twenty":-2.320475,"median":-1.625846,"eighty":-1.217877,"marketCap":496569789},{"date":"2024-11-15","current":-1.766791,"twenty":-2.31186,"median":-1.676743,"eighty":-1.221601,"marketCap":432561563},{"date":"2024-11-22","current":-1.725268,"twenty":-2.307988,"median":-1.693927,"eighty":-1.221601,"marketCap":422395604},{"date":"2024-11-29","current":-1.954681,"twenty":-2.306323,"median":-1.709478,"eighty":-1.229672,"marketCap":478562529},{"date":"2024-12-06","current":-2.388593,"twenty":-2.306323,"median":-1.725268,"eighty":-1.23169,"marketCap":584796802},{"date":"2024-12-13","current":-2.088591,"twenty":-2.321516,"median":-1.757967,"eighty":-1.238401,"marketCap":511347747},{"date":"2024-12-20","current":-2.024787,"twenty":-2.313583,"median":-1.76875,"eighty":-1.241197,"marketCap":495726646},{"date":"2024-12-27","current":-2.088883,"twenty":-2.309537,"median":-1.777713,"eighty":-1.243092,"marketCap":511419083},{"date":"2025-01-03","current":-1.778913,"twenty":-2.307156,"median":-1.777862,"eighty":-1.244452,"marketCap":435529430},{"date":"2025-01-10","current":-1.777862,"twenty":-2.305849,"median":-1.777862,"eighty":-1.244878,"marketCap":435272177},{"date":"2025-01-17","current":-1.989062,"twenty":-2.304427,"median":-1.779554,"eighty":-1.246554,"marketCap":486980042},{"date":"2025-01-24","current":-2.040548,"twenty":-2.299664,"median":-1.784789,"eighty":-1.253258,"marketCap":499585442},{"date":"2025-01-31","current":-2.036345,"twenty":-2.283748,"median":-1.80308,"eighty":-1.272811,"marketCap":498556430},{"date":"2025-02-07","current":-1.976453,"twenty":-2.276485,"median":-1.8278,"eighty":-1.28026,"marketCap":483893005},{"date":"2025-02-14","current":-1.999569,"twenty":-2.273364,"median":-1.845442,"eighty":-1.299813,"marketCap":489552573},{"date":"2025-02-21","current":-2.060513,"twenty":-2.263946,"median":-1.859179,"eighty":-1.303538,"marketCap":504473250},{"date":"2025-02-28","current":-1.892393,"twenty":-2.258524,"median":-1.87682,"eighty":-1.306703,"marketCap":463312761},{"date":"2025-03-07","current":-1.875581,"twenty":-2.211367,"median":-1.875581,"eighty":-1.307262,"marketCap":459196712},{"date":"2025-03-14","current":-5.557927,"twenty":-2.211367,"median":-1.881886,"eighty":-1.317995,"marketCap":430316947},{"date":"2025-03-21","current":-5.33039,"twenty":-2.277938,"median":-1.88594,"eighty":-1.323353,"marketCap":412700118},{"date":"2025-03-28","current":-4.805047,"twenty":-2.306323,"median":-1.893969,"eighty":-1.325512,"marketCap":372025970},{"date":"2025-04-04","current":-4.129128,"twenty":-2.32984,"median":-1.905491,"eighty":-1.337057,"marketCap":319693626},{"date":"2025-04-11","current":-3.466594,"twenty":-2.375387,"median":-1.926854,"eighty":-1.34432,"marketCap":268397566},{"date":"2025-04-17","current":-3.536863,"twenty":-2.423443,"median":-1.931271,"eighty":-1.357169,"marketCap":273838057},{"date":"2025-04-25","current":-4.03209,"twenty":-2.511189,"median":-1.940728,"eighty":-1.376163,"marketCap":312180567}],"updateTime":1745740139914}}}